Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage
To provide children dependent on total parenteral nutrition with Omegaven®, a fish oil-based intravenous lipid emulsion that may be less hepatotoxic than conventional, vegetable oil-based intravenous lipid emulsions, and that may therefore reduce the need for liver transplantation.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||A Safer Approach to Total Parenteral Nutrition in Pediatric Short Bowel Syndrome Intended to Decrease the Frequency and Severity of Liver Damage|
Drug: Omegaven 10%
Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.
Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN
Please refer to this study by its ClinicalTrials.gov identifier: NCT01861834
|Contact: Stuart S. Kaufman, MD||202-444-0906|
|United States, District of Columbia|
|MedStar Georgetown Transplant Institute|
|Washington, District of Columbia, United States, 20007|
|Principal Investigator: Stuart Kaufman, MD|